Efudex Articles
R-PR's Irinotecan And Colorectal Cancer
13 February 1995
R-PR Submits First Licence Application For Irinotecan
2 January 1995
Phase II Results With Zeneca's Tomudex
28 November 1994
Lilly's Gemcitabine; First Phase III Results
28 November 1994
Euro CPMP Views Janssen Drug
7 November 1994
Nippon Shoji "Aware of Usevir Effects"
22 August 1994
NICOTINE PATCH AND SKIN TOXICITY
27 June 1994
CONFERENCE REPORT: ASCO MEETING
30 May 1994
TAXOTERE REVEALS BROAD ACTIVITY
23 May 1994
MATRIX ANTICANCER GEL: PRECLIN DATA
9 May 1994
MORE ON NETIVUDINE WITHDRAWAL
4 April 1994
NEW TRIAL DATA ON R-PR'S TAXOTERE
21 March 1994
IMMUNEX AIMS FOR THREE DRUGS IN CLINIC IN 1994
21 February 1994
IRINOTECAN BACKED IN JAPAN AMID CONCERNS
13 December 1993
USEVIR PULLED AS DEATHS FOLLOW LAUNCH
25 October 1993
EC CPMP DIVIDED ON LEVAMISOL APPROVAL
28 June 1993
PALA DOES NOT ENHANCE 5-FU
31 May 1993
PHASE II TRIALS OF MPI 5003 STARTED
31 May 1993
EXPANDING USES FOR INTERFERON ALPHA
31 May 1993
GLAXO COMPROMISES OVER ONDANSETRON PATENT
26 April 1993
PROFITS FALL AT KYOWA HAKKO
22 March 1993
WORLD ANTICANCER/ IMMUNOLOGY MARKET
8 February 1993
PHASE II RESULTS WITH MPI 5003
14 December 1992
J&J'S LEVAMISOLE "OVERPRICED"
1 June 1992
FRENCH FOLINIC ACID STUDY
13 April 1992
FRENCH FOLINIC ACID STUDY
13 April 1992
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
